Congenital Melanocytic Nevi: Where Are We Now?
Total Page:16
File Type:pdf, Size:1020Kb
Congenital melanocytic nevi: Where are we now? Part II. Treatment options and approach to treatment Omar A. Ibrahimi, MD, PhD,a,b Ali Alikhan, MD,c and Daniel B. Eisen, MDd Farmington, Connecticut; Boston, Massachusetts; Rochester, Minnesota; and Sacramento, California CME INSTRUCTIONS The following is a journal-based CME activity presented by the American Academy of available for their efficacy or lack thereof; and formulate a rational treatment Dermatology and is made up of four phases: approach. 1. Reading of the CME Information (delineated below) Date of release: October 2012 2. Reading of the Source Article Expiration date: October 2015 3. Achievement of a 70% or higher on the online Case-based Post Test 4. Completion of the Journal CME Evaluation Ó 2012 by the American Academy of Dermatology, Inc. http://dx.doi.org/10.1016/j.jaad.2012.06.022 CME INFORMATION AND DISCLOSURES Statement of Need: Technical requirements: The American Academy of Dermatology bases its CME activities on the Academy’s American Academy of Dermatology: core curriculum, identified professional practice gaps, the educational needs which d Supported browsers: FireFox (3 and higher), Google Chrome (5 and higher), underlie these gaps, and emerging clinical research findings. Learners should reflect Internet Explorer (7 and higher), Safari (5 and higher), Opera (10 and higher). upon clinical and scientific information presented in the article and determine the d JavaScript needs to be enabled. need for further study. Target Audience: Elsevier: Dermatologists and others involved in the delivery of dermatologic care. Technical Requirements This website can be viewed on a PC or Mac. We recommend a minimum of: Accreditation d PC: Windows NT, Windows 2000, Windows ME, or Windows XP The American Academy of Dermatology is accredited by the Accreditation Council d Mac: OS X for Continuing Medical Education to provide continuing medical education for d 128MB RAM physicians. d Processor speed of 500MHz or higher AMA PRA Credit Designation d 800x600 color monitor The American Academy of Dermatology designates this journal-based CME d Video or graphics card activity for a maximum of 1 AMA PRA Category 1 CreditsÔ. Physicians should d Sound card and speakers claim only the credit commensurate with the extent of their participation in the activity. Provider Contact Information: AAD Recognized Credit American Academy of Dermatology This journal-based CME activity is recognized by the American Academy of Phone: Toll-free: (866) 503-SKIN (7546); International: (847) 240-1280 Dermatology for 1 AAD Credit and may be used toward the American Academy of Fax: (847) 240-1859 Dermatology’s Continuing Medical Education Award. Mail: P.O. Box 4014; Schaumburg, IL 60168 Disclaimer: Confidentiality Statement: The American Academy of Dermatology is not responsible for statements made by American Academy of Dermatology: POLICY ON PRIVACY AND the author(s). Statements or opinions expressed in this activity reflect the views of the CONFIDENTIALITY author(s) and do not reflect the official policy of the American Academy of Privacy Policy - The American Academy of Dermatology (the Academy) is Dermatology. The information provided in this CME activity is for continuing committed to maintaining the privacy of the personal information of visitors to its education purposes only and is not meant to substitute for the independent medical sites. Our policies are designed to disclose the information collected and how it will judgment of a healthcare provider relative to the diagnostic, management and be used. This policy applies solely to the information provided while visiting this treatment options of a specific patient’s medical condition. website. The terms of the privacy policy do not govern personal information Disclosures furnished through any means other than this website (such as by telephone or mail). Editors E-mail Addresses and Other Personal Information - Personal information such The editors involved with this CME activity and all content validation/peer reviewers as postal and e-mail address may be used internally for maintaining member records, of this journal-based CME activity have reported no relevant financial relationships marketing purposes, and alerting customers or members of additional services with commercial interest(s). available. Phone numbers may also be used by the Academy when questions about Authors products or services ordered arise. The Academy will not reveal any information The authors of this journal-based CME activity have reported no relevant financial about an individual user to third parties except to comply with applicable laws or relationships with commercial interest(s). valid legal processes. Planners Cookies - A cookie is a small file stored on the site user’s computer or Web server and The planners involved with this journal-based CME activity have reported no relevant is used to aid Web navigation. Session cookies are temporary files created when a financial relationships with commercial interest(s). The editorial and education staff user signs in on the website or uses the personalized features (such as keeping track involved with this journal-based CME activity have reported no relevant financial of items in the shopping cart). Session cookies are removed when a user logs off or relationships with commercial interest(s). when the browser is closed. Persistent cookies are permanent files and must be deleted manually. Tracking or other information collected from persistent cookies or Resolution of Conflicts of Interest any session cookie is used strictly for the user’s efficient navigation of the site. In accordance with the ACCME Standards for Commercial Support of CME, the American Academy of Dermatology has implemented mechanisms, prior to the Links - This site may contain links to other sites. The Academy is not responsible for planning and implementation of this Journal-based CME activity, to identify and the privacy practices or the content of such websites. mitigate conflicts of interest for all individuals in a position to control the content of Children - This website is not designed or intended to attract children under the age this Journal-based CME activity. of 13. The Academy does not collect personal information from anyone it knows is under the age of 13. Learning Objectives After completing this learning activity, participants should be able to identify Elsevier: http://www.elsevier.com/wps/find/privacypolicy.cws_home/ treatments available for congenital melanocytic nevi; discuss the evidence privacypolicy 515.e1 515.e2 Ibrahimi, Alikhan, and Eisen JAM ACAD DERMATOL OCTOBER 2012 Treatment of congenital melanocytic nevi (CMN) is generally undertaken for 2 reasons: (1) to reduce the chances of cutaneous malignant melanoma and (2) for cosmetic reasons. Over the past century, a large number of treatments for CMN have been described in the literature. These include excision, dermabrasion, curettage, chemical peels, radiation therapy, cryotherapy, electrosurgery, and lasers. Only low-level evidence supporting these approaches is available, and large randomized controlled trials have not been published. This article explores therapeutic controversies and makes recommendations based on the best available evidence. ( J Am Acad Dermatol 2012;67:515.e1-13.) The treatment of congen- d High rates of satisfac- ital melanocytic nevi (CMN) CAPSULE SUMMARY tion have been reported before the development of for excision when CMN malignancy is considered d Excision has been recommended as the are \20 cm in size, es- for 2 reasons: (1) to reduce first-line treatment for congenital nevi in pecially for those on the chances of cutaneous which treatment is indicated. the head and neck malignant melanoma (MM) d Data regarding the purported benefits Excision can be per- and (2) for cosmetic reasons. and risks of these procedures are formed either for cosmetic The treatment of giant CMN explored. (GCMN) is technically diffi- reasons or to attempt to re- d Excision may result in high satisfaction, duce the risk of development cult, and complete removal but its efficacy at reducing the incidence of MM. Given that CMN may of these lesions is often of malignant melanoma is unproven. penetrate deeply, excision to impossible. Approaches to d the level of the fascia is ad- removal can broadly be Fears regarding the use of lasers for vocated in order to assure classified into 2 groups: treatment are unsubstantiated, but removal of as much of the full- and partial-thickness treatment effectiveness with lasers has lesion as possible and to removal procedures (Table been variable. I). Full-thickness procedures avoid recurrence. However, the excision of CMN to re- remove the entire dermis and duce the chance of malignancy is controversial. epidermis and varying amounts of subcutaneous Proponents claim that the removal of these nevi tissue. They are likely to remove more nevus cells reduce the risk of associated MM.1 Although the than partial-thickness procedures, but the effective- absolute risk of MM in many studies appears to be ness of either method for preventing future malig- low, it is still considerably higher than the general nancy remains a topic of debate. It is important to population.1 In addition, the true lifetime risk of MM stress that lifelong surveillance is warranted regard- may be underestimated given the skewing towards a less of if partial- or full-thickness treatments are younger average age of patients in many studies. In undertaken. the case of GCMN,